Alexandre Loupy
Hôpital Necker-Enfants Malades · 478 works · 20,280 citations · h-index 67
Top works
- Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions
- The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
- Preexisting Donor-Specific HLA Antibodies Predict Outcome in Kidney Transplantation
- Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival
- Organ procurement and transplantation during the COVID-19 pandemic
- The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology
- The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody-mediated rejection
- A 2018 Reference Guide to the Banff Classification of Renal Allograft Pathology
- Outcome of Subclinical Antibody-Mediated Rejection in Kidney Transplant Recipients with Preformed Donor-Specific Antibodies
- Antibody-mediated vascular rejection of kidney allografts: a population-based study
- Antibody-Mediated Rejection of Solid-Organ Allografts
- Significance of C4d Banff Scores in Early Protocol Biopsies of Kidney Transplant Recipients with Preformed Donor-Specific Antibodies (DSA)
- The impact of donor-specific anti-HLA antibodies on late kidney allograft failure
- Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts
- Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study
- COVID-19 pandemic and worldwide organ transplantation: a population-based study
- Molecular Diagnosis of Antibody-Mediated Rejection in Human Kidney Transplants
- Disparities in Acceptance of Deceased Donor Kidneys Between the United States and France and Estimated Effects of Increased US Acceptance
- Assessment of Tocilizumab (Anti–Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients
- IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury